Objective: Because exogenous estrogen treatment has been associated with a higher risk of urinary incontinence, our objective was to evaluate the longitudinal relationships of dietary phytoestrogen intakes (isoflavones, coumestans, and lignans) and the development of incontinence in midlife women transitioning through menopause.
xogenous estrogen has been used variably to treat urinary incontinence. Although systemic, conjugated equine estrogens are associated with the development and worsening of both stress and urge incontinence in postmenopausal women 1<3 ; other types and routes of estrogens have not been as well studied, with mixed results. 4 Selective estrogen receptor modulators (SERMs) have variable effects on incontinence. For example, testing of levormeloxifene (a SERM with high estrogenic activity in urogenital tissues) 5<7 was halted in part because of an associated fourfold increased incidence of incontinence (from 4% to 17%). 8 In addition, the development of incontinence seemed to be dose related, with a higher rate of incontinence among women taking higher levormeloxifene doses. 9 Meanwhile, raloxifene (a SERM with low estrogenic activity in urogenital tissues) had no effect on incontinence. 10 The clinical effect of pharmaceutical estrogens and SERMs on incontinence raises interest in the effects of dietary sources of estrogen receptorYmodulating compounds. 11, 12 Phytoestrogens (Bplant estrogens[) are heterocyclic phenols found in many plant foods. The general class of phytoestrogens is divided into three major categories: isoflavones (eg, daidzein and genistein), coumestans (eg, coumestrol), and lignans (eg, secoisolariciresinol and matairesinol). Based on the primary action of these classes on estrogen receptors and on the highest level of evidence that the action of systemic estrogens increases the risk of developing incontinence, we hypothesized that isoflavones' and coumestrol's more agonistic action would be associated with an increased risk of developing both stress and urge incontinence, whereas lignans' more antagonistic action would reduce the occurrence of both incontinence types. 13 Scant data evaluate the effects of individual phytoestrogen classes on incontinence. In one small pilot trial, 12 weeks of a Bphytoestrogen-deficient diet[ was associated with an increased frequency of urge incontinence only, whereas a soy (isoflavone)Yrich diet did not affect incontinence. 11 These results encourage further investigation of the effects of phytoestrogens on incontinence, but large epidemiological studies are first needed to explore associations between different classes of dietary phytoestrogens and incontinence.
Our objective was to evaluate the longitudinal relationships of dietary intakes of isoflavones, coumestans, or lignans and the development of incontinence in midlife women transitioning through menopause.
METHODS

Study sample
The Study of Women's Health Across the Nation (SWAN) Phytoestrogen Study sample is derived from participants in SWAN, a community-based, multisite, multiracial/ethnic, prospective cohort study of the menopausal transition and midlife. 14 Briefly, entry criteria for the SWAN cohort were as follows: aged 42 to 52 years; with at least one ovary and an intact uterus; no current use of estrogens or other medications known to affect ovarian function; have had at least one menstrual period in the 3 months before screening; and selfidentification as white, African American, Hispanic, Chinese, or Japanese. Women in SWAN have been followed for more than 10 years at seven sites. Usual dietary intake data were collected using a food frequency questionnaire (FFQ) administered at baseline and on follow-up visits 5 and 9. In the SWAN Phytoestrogen Study, participants from six SWAN sites (Boston, Chicago, Detroit, Pittsburgh, Oakland, and Los Angeles; N = 2,870) were eligible for inclusion. We omitted data from one SWAN site (Newark) because of high attrition (up to 45%) and because that site did not collect any dietary data on follow-up 9. We also excluded participants based on availability of diet data and dietary quality control standards as follows: did not have diet assessment (n = 11); reported intake of fewer than 4 or more than 17 solid foods per day (n = 130); skipped more than 10 food items when responding to the FFQ (n = 1); and had a calculated daily energy intake lower than 500 kcal or higher than 5,000 kcal (n = 7). If participants met any of these diet-based exclusionary criteria at later visits, we set their dietary variables to missing for those visits. Thus, the SWAN Phytoestrogen Study sample consists of 2,721 women at baseline, 1,905 on follow-up visit 5, and 1,677 on follow-up visit 9. Inclusion in the current study of phytoestrogens and incontinence required that participants reported no incontinence at baseline so that they could be followed for new reports of incontinence (n = 1,459 women at baseline, n = 981 women on follow-up visit 5, and n = 883 women on follow-up visit 9).
Phytoestrogen intake
At baseline and on follow-up visits 5 and 9, SWAN used an interviewer-administered dietary assessment to determine usual food consumption during the past year. The SWAN diet instrument had three components: (1) a full FFQ, (2) Women who were continent at baseline but reported incontinence at any of the annual follow-up visits were considered to have incident incontinence and were compared with women who did not develop incontinence during the same time frame.
When a woman was missing data on the frequency and type of incontinence from one or two visits, we imputed values as follows. 18, 19 If the missing value occurred on year 10, we imputed the value on the previous visit. If a woman reported no incontinence in the years previous and subsequent to a missing incontinence report, we assumed no incontinence in those missng years. If a woman was missing incontinence data in the 1 to 2 years previous to a first report of incontinence, we randomly assigned her missing values to either no incontinence or the frequency and/or type of incontinence in that subsequent year. We imputed incontinence frequency for 1,959 observations (6.5% of all observations) and incontinence type for 3,207 observations (10.7% of all observations).
Other covariates
Our baseline covariates included baseline age, body mass index (BMI), diabetes, parity, socioeconomic status, education, number of premenstrual symptoms, and symptom sensitivity from the first annual follow-up visit. Time-dependent covariates were menopause stage, hormone use, perceived stress, sex hormoneYbinding globulin level, and estradiol (E 2 ) level. We also evaluated time-varying covariates from the previous visit (lagged) because we would anticipate incontinence to develop or not develop after the emergence of or change in the variable: incident diabetes, hypertension, depressive and anxiety symptoms, smoking status, weight change (current year value subtracted from previous year value, in pounds), number of stressful life events, overall health, and energy intake.
Covariates were ascertained by the following methods. SWAN classified the menopausal transition stage annually from menstrual bleeding patterns. Premenopause was less than 3 months of amenorrhea and no menstrual irregularities in the previous year. Early perimenopause was less than 3 months of amenorrhea and some menstrual irregularities in the previous year. Late perimenopause was 3 to 11 months of amenorrhea. Postmenopause was 12 consecutive months of amenorrhea. We calculated BMI (weight in kilograms/ [height in meters] 2 ) based on measurements taken annually by certified staff who used calibrated scales and a stadiometer. Screening socioeconomic status was approximated by the level of difficulty paying for basics (food, heat, and shelter). Interviewers obtained self-reported medical histories, smoking history, and medication use. We considered a woman as having diabetes if she reported the diagnosis of diabetes or reported the use of diabetes medications. Each year, SWAN used the same questions from the Center for Epidemiological Studies-Depression scale 20 (we defined depressive symptoms as a score of Q16), the Medical Outcomes Study Social Support Survey, 21 the Life Stressors and Social Resources Inventory, 22 and the Psychiatric Epidemiology Research Interview. 23 SWAN measured anxiety symptoms by a summed score of days in the past 2 weeks in which certain symptoms were experienced (grouchiness or irritability, feeling tense or nervous, pounding or racing heart, and feeling fear for no reason); we defined anxiety symptoms by a score of 4 or higher. 24 On year 1 only, SWAN combined responses to questions assessing sensitivity to physical sensations into a Symptom Sensitivity Scale. 25 For E 2 , SWAN used a rabbit antiYE 2 -6 ACS-180 immunoassay with a lower limit of detection of 1.0 pg/mL and conducted duplicate E 2 assays with results reported as the arithmetic mean for each participant (coefficient of variation, 3%-12%). We adjusted these levels by day of menstrual cycle for women still having periods and sex hormoneY binding globulin.
Phytoestrogen interpolation
SWAN measured study outcomes annually, but dietary exposure variables were measured only on visits 00, 05, and 09. To handle differences in measurement schedules, we interpo-lated dietary variables one at a time using random effects modeling as a function of time on study, 26 after applying log transformation due to right skewness. These models were stratified on race because of large racial/ethnic differences in phytoestrogen consumption. Loess curves indicated linear time trends; thus, each model included a random (woman-specific) intercept and slope for time on study. The woman-specific regression coefficients are weighted averages of coefficients from the full sample and coefficients from each participant's data only. 27 Adding predictors other than time on study did little to improve prediction, and missing predictor data reduced the available sample size.
To assess the performance of these models, we compared fitted values with observed values from visits 00, 05, and 09. R values between fitted and observed values, accounting for within-woman correlation, 28 ranged from 0.978 to 0.996, indicating excellent agreement. In addition, linear regressions of observed values on fitted values indicated no systematic bias, as intercepts were close to 0 and slopes were close to 1. Finally, Loess curves for observed values versus time on study overlapped considerably with corresponding curves for fitted values.
We interpolated (ie, imputed) logged dietary variables for visits on which the FFQ was not administered, using the participant-specific intercept and slope coefficients and the relevant value of time on study for each non-FFQ study visit. Given the high agreement between observed and fitted values, we did not use multiple imputation. In addition, we ran two sets of sensitivity analyses: first, including only predictor and outcome data observed on FFQ visits (00, 05, and 09), and, second, including all visits in analyses but carrying the last measured dietary variable value forward, which implicitly imputes based on only a single previous observation, in contrast to the model-based imputation based on all of a woman's observed FFQ data. Results from these sensitivity analyses were similar to those using interpolated dietary values, except on two occasions. Specifically, there was a statistically significant association in the same positive direction between the second tertile of ligand intake and stress incontinence where there had been none in the non-Asian group, and no association between the second tertile of isoflavone intake and stress incontinence in the Asian group where there had been one (data not shown). Although these results suggest that some differences in interpolation may affect the significance of our results, the lack of a monotonic association and similar odds ratios suggest no important effect. Thus, we present the interpolated results, which we believe to be more representative of phytoestrogen intakes. 29 phytoestrogen intakes. Because these intake distributions had little overlap, we categorized women into Asian (Chinese and Japanese) and non-Asian (white and African American) racial groups for our analyses (Fig. 1) . For consistency between isoflavones, coumestrol, and lignans, and to allow for possible nonlinear associations, we categorized each phytoestrogen class based on tertiles in the Asian and non-Asian subgroups and ran relational analyses in stratified samples of Asian and non-Asian women.
We compared the proportions and means of each variable at baseline for women who did and did not develop incontinence using W 2 test and Wilcoxon sign rank test for categorical and continuous variables, respectively. For baseline phytoestrogen class comparisons, we used the Wilcoxon sign rank test because of skewness. We used discrete proportional hazards models 30 to evaluate whether phytoestrogen intake on the previous visit was associated with the development of monthly or more incontinence compared with no development of any incontinence at the current visit. For all our analyses, we evaluated phytoestrogen consumption from the previous visit to ensure that the dietary exposures preceded new-onset incontinence. We created similar separate models for stress and urge incontinence. For stress incontinence, our comparison group was those women who had no development of stress incontinence; for urge incontinence, our comparison group was those women who had no development of urge incontinence.
The candidate covariates described above were chosen based on the literature, a priori hypotheses, and/or association with the outcome in univariable analysis at P G 0.10. We also adjusted for correlates of the missing FFQ data that reduced our sample size over the studyVincluding ethnicity (stratifying factor), education level, weight, and anxietyVto reduce possible nonresponse bias. 31 We used SAS version 9.2 (SAS Institute Inc., Cary, NC).
RESULTS
Women who developed incontinence (incident incontinence) differed in several ways from women who remained continent.
Those with new-onset incontinence had a higher level of education; reported less economic hardship (ie, had an easier time paying for basic necessities); were more likely to have diabetes, higher BMI, and higher energy intake; and were more likely to report anxiety symptoms, premenstrual symptoms, and life stressors compared with women who never reported incontinence ( Table 1) .
The mean intakes of isoflavones were about 10-fold lower in the non-Asian group compared with the Asian group. Coumestrol intake in non-Asians was about half that in the Asian group, whereas lignan intake was only slightly lower ( Table 2) .
During the 10 years of observation, the number of women reporting new-onset monthly or more incontinence of any type declined ( Table 3 ). The cumulative incidence rate of the entire sample for 10 years for any incontinence was 135 per 1,000 person-years. Asian women had a lower cumulative incidence of incontinence (105 per 1,000 person-years) than non-Asian women (146 per 1,000 person-years), with urge incontinence being more common in the non-Asian group (92 per 1,000 person-years) than in the Asian group (53 per 1,000 person-years), but with stress incontinence being more similar (95 per 1,000 person-years in non-Asians versus 92 per 1,000 person-years in Asians).
In both unadjusted and multivariable models, we found no statistically significant (P G 0.05) or consistent patterns of association between developing any incontinence or specific subtypes (stress or urge incontinence) and the reported dietary intake of isoflavones, coumestrol, or lignans. Exposure to each class of phytoestrogen was estimated based on the visit previous to the reported onset of incontinence (Table 4) . Although Asian and non-Asian women have different intake ranges of each phytoestrogen class ( Fig. 1) , our results show that, within these ranges, dietary phytoestrogens did not prevent or increase the odds of developing incontinence of any type, regardless of menopausal stage.
DISCUSSION
> and A estrogen receptors have been variably identified in urogenital tissues (bladder, urethra, vaginal mucosa, levator ani muscles, and pubocervical fascia 32<34 ) and in the central and peripheral nervous systems. 35 Exogenous estrogen seems to reduce collagen concentration, decrease the cross-linking of collagen, 36 and increase the levels of collagen turnover in periurethral tissues, 37<39 which may lead to weakened urethral support and stress incontinence. In animal studies, estrogen increases the collagen-to-smooth muscle ratio in the bladder wall, increasing mean resting bladder tension and contractility, which may impact urge incontinence. 40<42 Although the effects on the continence mechanism are unknown, estrogen has a neuromodulating function, increasing sympathetic nerve density in the pelvis and regulating neurotrophins. 43 We found no association between the reported dietary intakes of three phytoestrogen classes (isoflavones, coumestrol, or lignans) and developing any type of incontinence in women transitioning through menopause. A number of explanations account for this null finding. Although estrogen treatment is most probably associated with developing incontinence, the phytoestrogens we studied may have no discernible effects owing to lower binding affinities for the estrogen receptors compared with E 2 . 13 In addition, phytoestrogens bind > and A receptors with different affinities and with different agonist and antagonistic properties, 13 so the balance of this binding variation for isoflavones, coumestrol, and lignans in the urogenital tract in midlife women may not produce tissue effects that predispose to stress or urge incontinence.
We chose to evaluate phytoestrogen consumption in the year previous to the first report of monthly or more incontinence to be certain that the isoflavone, coumestrol, and lignan dietary intake levels of interest would precede that incident episode. In our interpolation process, we found very little within-woman variation in phytoestrogen intake from year to year, and so those levels were probably similar through the year of the incident incontinence episode. Because the levels of phytoestrogen intake in SWAN Asian participants had medians and ranges different from those in non-Asian women, we avoided colinearity between race and phytoestrogen intake by creating stratified models using Asian and non-Asian tertiles. Although exposure levels in Asian and non-Asian strata were unequal (ie, the highest isoflavone tertile in non-Asians was roughly equivalent to the lowest isoflavone tertile in Asians), we did not find any association between phytoestrogen intake and incontinence in either group, and so it is improbable that racial dissimilarities in food sources or other factors are important in our null findings.
Evaluation of phytoestrogen effects on women's health outcomes have had varied results. About 30% to 50% of individuals have gut bacteria that metabolize some phytoestrogens into more active serum metabolites, and variation in metabolite production may account for differences in the clinical effects of phytoestrogen intake across studies of, for example, bone density and hot flushes. 44 Because our study evaluated dietary intake of phytoestrogens, we could not determine whether different serum concentrations of more active metabolites may prevent or promote the development of incontinence.
Other limitations of our study include the unavoidable measurement error in underestimating phytonutrient intakes and the small-area variation in the isoflavone content of soy crops that can lead to inaccuracies. 45 Yet the relative rankings of phytonutrient intakes are probably robust, and SWAN minimized differential misclassification by designing the FFQs to accommodate mixed dishes and to account for ethnic foods. Although attrition in longitudinal analyses may affect the generalizability of our results, we included as predictors important factors correlated with attrition to account for possible nonresponse bias.
The incidence of incontinence declined during the time frame of our study. Explanations for this finding include a lower incidence in early postmenopause, which coincides with the later years of the study for most women, and a significant reduction in the women at risk for incontinence during the course of the study, given how common incontinence is in midlife women and how common cohort attrition is in longitudinal analysis. Our incontinence outcomes were self-reported and have the advantage of reflecting women's experience of incontinence, but the disadvantage of lower precision in diagnosing the type (stress and urge) of incontinence. SWAN used the same incontinence questions on an annual basis. These questions were similar to validated questions and those that have been used widely in other epidemiological studies of incontinence type. 46, 47 The sensitivity and specificity of self-reported stress and urge incontinence are estimated at 71% to 85% and 60% to 79%, respectively, in validated questionnaires. 48, 49 CONCLUSIONS Although epidemiological studies showing no association are often deemed uninteresting, the results of this longitudinal study provide important information to better understand the Any  59  23  27  20  13  9  7  3  5  7  Stress  53  31  23  17  10  10  7  5  9  7  Urge  34  22  22  20  12  9  6  13  11  13  Non-Asians  Any  274  142  80  61  47  22  30  22  15  13  Stress  221  130  89  57  42  24  38  32  21  8  Urge  258  146  103  68  44  36  59  33  39 Any incontinence refers to the first report of stress, urge, or both in women who reported no incontinence in the previous years. Stress incontinence refers to the first report of stress incontinence in women who reported no stress incontinence in the previous years. Urge incontinence refers to the first report of urge incontinence in women who reported no urge incontinence in the previous years. 0.10 (0.88-1.37) All models were adjusted for study time, menopause status, weight changes, life events, anxiety symptoms, total energy intake, education level, parity, history of premenstrual symptoms, baseline age, baseline body mass index, symptom sensitivity, sex hormoneYbinding globulin, estradiol, and day of cycle that sera for estradiol and sex hormoneYbinding globulin were obtained. OR, odds ratio; Ref, reference. a Asians, number of observations: any incontinence (n = 1,343), stress incontinence (n = 1,524), and urge incontinence (n = 2,490) b Non-Asians, number of observations: any incontinence (n = 3,333), stress incontinence (n = 4,810), and urge incontinence (n = 6,423) role of estrogenlike substances on the continence mechanism of midlife women. Our study has important generalizable public health relevance showing that neither high nor low dietary intakes of isoflavones, coumestrol, or lignans prevent stress or urge incontinence. Before concluding that phytoestrogens have no effect on incontinence, however, future studies should evaluate whether individual variations in phytoestrogen metabolism, measured by serum levels of phytoestrogens and/or their metabolites, impact incontinence symptoms.
